首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1489259

全球注意力不足過動症市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Attention Deficit Hyperactivity Disorder Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月01日 | 出版商:

Value Market Research | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球注意力不足過動症市場需求預計將從 2023 年的 193.2 億美元達到 2032 年近 280 億美元的市場規模，2024-2032 年研究期間複合年成長率為 4.21%。

注意力不足過動症 (ADHD) 是一種神經發育疾病，其特徵是過動、注意力不集中和衝動，可能會擾亂日常功能。它通常出現在兒童期，但可以持續到成年。患有多動症的人發現維持專注力、完成任務、組織活動和調節衝動具有挑戰性。 ADHD 的確切原因尚不完全清楚，但據信涉及遺傳、環境和神經因素。診斷通常依賴臨床評估和行為評估。治療通常包括行為療法、藥物和生活方式調整，以幫助控制症狀和改善生活品質。

市場動態

注意力不足過動症 (ADHD) 市場主要是由兒童和成人 ADHD 診斷盛行率上升所推動的。對多動症症狀的認知和理解的提高導致更多的人尋求醫療幫助和接受診斷。人們對心理健康問題的接受度的提高以及對過動症的恥辱感的減少也促進了市場的成長。此外，藥物治療的進步和功效增強、副作用較少的新藥也推動了市場的發展。擴大針對過動症患者的行為療法和支持服務是醫療治療的補充，推動了市場的全面成長。此外，旨在了解過動症遺傳和環境因素的研發活動不斷增加，正在推動注意力不足過動症市場向前發展。然而，恥辱和誤診問題可能會挑戰未來幾年註意力不足過動症市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球注意力不足過動症市場的各個細分市場進行了包容性評估。注意力不足過動症產業的成長和趨勢為本研究提供了整體方法。

市場區隔

注意力不足過動症市場報告的這一部分提供了國家和地區層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

依藥物類型

興奮劑（安非他明、哌醋甲酯、賴右安非他命、右旋哌甲酯）
非興奮劑（托莫西汀、胍法辛、可樂定等）

按人口統計

孩子們
成年人

按配銷通路

零售藥房
醫院藥房

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的注意力不足過動症市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。注意力不足過動症市場的主要參與者包括諾華公司、禮來公司、強生服務公司、Lupin、武田製藥有限公司、Mallinckrodt Plc.、輝瑞公司、普渡製藥有限公司、Aytu BioPharma Inc.（ NEOS Therapeutics Inc.)、Supernus Pharmaceuticals Inc.。進展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：注意力不足過動症公司的競爭格局

注意力不足過動症市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Novartis AG

公司簡介
公司收入
產品
最近的發展

Eli Lilly And Company

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson Services Inc.

公司簡介
公司收入
產品
最近的發展

Lupin

公司簡介
公司收入
產品
最近的發展

Takeda Pharmaceutical Company Limited

公司簡介
公司收入
產品
最近的發展

Mallinckrodt Plc.

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Purdue Pharma LP

公司簡介
公司收入
產品
最近的發展

Aytu BioPharma Inc. (NEOS Therapeutics Inc.)

公司簡介
公司收入
產品
最近的發展

Supernus Pharmaceuticals Inc

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114726

The global demand for Attention Deficit Hyperactivity Disorder Market is presumed to reach the market size of nearly USD 28 Billion by 2032 from USD 19.32 Billion in 2023 with a CAGR of 4.21% under the study period 2024-2032.

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition featuring symptoms of hyperactivity, inattention, and impulsivity, which can disrupt daily functioning. It commonly presents in childhood but can continue into adulthood. Individuals with ADHD find it challenging to sustain attention, accomplish tasks, organize activities, and regulate impulses. The exact cause of ADHD is not wholly understood but is believed to involve genetic, environmental, and neurological factors. Diagnosis typically relies on clinical evaluation and behavioral assessments. Treatment often includes behavioral therapy, medication, and lifestyle adjustments to help manage symptoms and improve quality of life.

MARKET DYNAMICS

The attention deficit hyperactivity disorder (ADHD) market is primarily driven by the rising prevalence of ADHD diagnoses among children and adults. Increased awareness and better understanding of ADHD symptoms have led to more individuals seeking medical help and receiving diagnoses. The spurring acceptance of mental health issues and the reduction of stigma surrounding ADHD have also contributed to market growth. Furthermore, advancements in pharmaceutical treatments and new medications with enhanced efficacy and fewer side effects have boosted the market. Expanding behavioral therapies and support services for ADHD patients complements medical treatments, driving comprehensive market growth. Additionally, increasing research & development activities aimed at understanding the genetic and environmental factors of ADHD are propelling the attention deficit hyperactivity disorder market forward. However, stigma and misdiagnosis issues may challenge the attention deficit hyperactivity disorder market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Attention Deficit Hyperactivity Disorder. The growth and trends of Attention Deficit Hyperactivity Disorder industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Attention Deficit Hyperactivity Disorder market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate)
Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others)

By Demographics

Children
Adults

By Distribution Channel

Retail Pharmacy
Hospital Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Attention Deficit Hyperactivity Disorder market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Attention Deficit Hyperactivity Disorder market include Novartis AG, Eli Lilly And Company, Johnson & Johnson Services Inc., Lupin, Takeda Pharmaceutical Company Limited, Mallinckrodt Plc., Pfizer Inc., Purdue Pharma L.P., Aytu BioPharma Inc. (NEOS Therapeutics Inc.), Supernus Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ATTENTION DEFICIT HYPERACTIVITY DISORDER - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Demographics
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data Analysis By Drug Type
5.3. Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Historic and Forecast Sales By Regions
5.4. Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Historic and Forecast Sales By Regions

6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DEMOGRAPHICS

6.1. Overview By Demographics
6.2. Historical and Forecast Data Analysis By Demographics
6.3. Children Historic and Forecast Sales By Regions
6.4. Adults Historic and Forecast Sales By Regions

7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data Analysis By Distribution Channel
7.3. Retail Pharmacy Historic and Forecast Sales By Regions
7.4. Hospital Pharmacy Historic and Forecast Sales By Regions

8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ATTENTION DEFICIT HYPERACTIVITY DISORDER COMPANIES

9.1. Attention Deficit Hyperactivity Disorder Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF ATTENTION DEFICIT HYPERACTIVITY DISORDER INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Novartis AG
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Eli Lilly And Company
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Johnson & Johnson Services Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Lupin
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Takeda Pharmaceutical Company Limited
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Mallinckrodt Plc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Pfizer Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Purdue Pharma L.P.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Aytu BioPharma Inc. (NEOS Therapeutics Inc.)
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Supernus Pharmaceuticals Inc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

簡介目錄圖表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Drug Type (USD MN)
Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Market Sales By Geography (USD MN)
Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Market Sales By Geography (USD MN)
Analysis By Demographics (USD MN)
Children Market Sales By Geography (USD MN)
Adults Market Sales By Geography (USD MN)
Analysis By Distribution Channel (USD MN)
Retail Pharmacy Market Sales By Geography (USD MN)
Hospital Pharmacy Market Sales By Geography (USD MN)
Global Attention Deficit Hyperactivity Disorder Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Attention Deficit Hyperactivity Disorder Report
Market Research Process
Market Research Methodology
Global Attention Deficit Hyperactivity Disorder Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Drug Type
Market Attractiveness Analysis By Demographics
Market Attractiveness Analysis By Distribution Channel
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Drug Type (USD MN)
Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Market Sales By Geography (USD MN)
Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Market Sales By Geography (USD MN)
Global Market Analysis By Demographics (USD MN)
Children Market Sales By Geography (USD MN)
Adults Market Sales By Geography (USD MN)
Global Market Analysis By Distribution Channel (USD MN)
Retail Pharmacy Market Sales By Geography (USD MN)
Hospital Pharmacy Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis